CL2019000019A1 - Anticuerpos con baja inmunogenicidad y uso de los mismos - Google Patents

Anticuerpos con baja inmunogenicidad y uso de los mismos

Info

Publication number
CL2019000019A1
CL2019000019A1 CL2019000019A CL2019000019A CL2019000019A1 CL 2019000019 A1 CL2019000019 A1 CL 2019000019A1 CL 2019000019 A CL2019000019 A CL 2019000019A CL 2019000019 A CL2019000019 A CL 2019000019A CL 2019000019 A1 CL2019000019 A1 CL 2019000019A1
Authority
CL
Chile
Prior art keywords
antibodies
low immunogenicity
methods
antigen binding
binding fragments
Prior art date
Application number
CL2019000019A
Other languages
English (en)
Inventor
Kandasamy Hariharan
Jeonghoon Sun
Jeffrey C Johnson
Lawrence Dearth
Haralambos Hadjivassiliou
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2019000019A1 publication Critical patent/CL2019000019A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan anticuerpos y fragmentos de unión al antígeno de estos con inmunogenicidad baja o nula en seres humanos y opcionalmente con características de fabricación deseables. También se proporcionan composiciones que comprenden dichos anticuerpos o fragmentos de unión al antígeno, métodos para utilizar dichos anticuerpos, y métodos para elaborar dichos anticuerpos.
CL2019000019A 2016-07-06 2019-01-04 Anticuerpos con baja inmunogenicidad y uso de los mismos CL2019000019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
CL2019000019A1 true CL2019000019A1 (es) 2019-06-28

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000019A CL2019000019A1 (es) 2016-07-06 2019-01-04 Anticuerpos con baja inmunogenicidad y uso de los mismos

Country Status (19)

Country Link
US (1) US11427632B2 (es)
EP (1) EP3481862A4 (es)
JP (1) JP7120989B2 (es)
KR (1) KR20190035737A (es)
CN (1) CN109689684B (es)
AR (1) AR108975A1 (es)
AU (1) AU2017292752B2 (es)
BR (1) BR112019000166A2 (es)
CA (1) CA3029977A1 (es)
CL (1) CL2019000019A1 (es)
CO (1) CO2019001112A2 (es)
EA (1) EA201990218A1 (es)
EC (1) ECSP19008417A (es)
IL (1) IL264009A (es)
MX (1) MX2019000172A (es)
SG (1) SG11201811788SA (es)
TW (1) TW201811824A (es)
WO (1) WO2018009499A1 (es)
ZA (1) ZA201900070B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
JP2023545983A (ja) 2020-10-07 2023-11-01 セルジーン コーポレイション リンパ系悪性腫瘍状態の二重特異性抗体治療
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0859841B1 (en) * 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
CN101189265B (zh) * 2005-06-01 2012-07-04 米克罗麦特股份公司 抗il2抗体
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
US8465741B2 (en) * 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
US8785604B2 (en) 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
ME03512B (me) * 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
WO2016081423A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
HK1245154A1 (zh) * 2014-12-30 2018-08-24 细胞基因公司 抗cd47抗体及其用途
US9650441B2 (en) * 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use

Also Published As

Publication number Publication date
KR20190035737A (ko) 2019-04-03
JP7120989B2 (ja) 2022-08-17
CN109689684B (zh) 2022-09-23
MX2019000172A (es) 2019-09-26
US20190241654A1 (en) 2019-08-08
AR108975A1 (es) 2018-10-17
ECSP19008417A (es) 2019-02-28
AU2017292752B2 (en) 2023-07-27
CN109689684A (zh) 2019-04-26
EP3481862A1 (en) 2019-05-15
US11427632B2 (en) 2022-08-30
CA3029977A1 (en) 2018-01-11
JP2019524087A (ja) 2019-09-05
TW201811824A (zh) 2018-04-01
EP3481862A4 (en) 2020-08-12
ZA201900070B (en) 2023-08-30
WO2018009499A1 (en) 2018-01-11
EA201990218A1 (ru) 2019-07-31
IL264009A (en) 2019-01-31
CO2019001112A2 (es) 2019-02-19
SG11201811788SA (en) 2019-01-30
AU2017292752A1 (en) 2019-01-24
BR112019000166A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
MX383464B (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
MX2018012076A (es) Composiciones y anticuerpos anti proteina 3 que contiene inmunoglobulina de linfocitos t y el dominio de mucina (tim-3).
CO2018003436A2 (es) Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso
MX2019004690A (es) Constructos de anticuerpos.
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CO2019001112A2 (es) Anticuerpos con inmunogenicidad baja y usos de estos referencia cruzada a solicitudes relacionadas
UY37279A (es) Anticuerpos tgf-beta y fragmentos de unión de los mismos
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2015016627A (es) Vacuna para la malaria.
BR112017023131A2 (pt) anticorpos anti- fcrn
MX382409B (es) Variantes de proteinas de unión al factor h y métodos de uso de estas.
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
CY1119912T1 (el) Αντιγονα και συνδυασμοι αντιγονων pseudomonas
AR095939A1 (es) Vacuna contra garrapatas rhipicephalus
AR115987A1 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso